Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism

No abstract is available for this paper.

• Publication year

  2008

• Venue

  The Pharmacogenomics Journal

• Publication date

  2008-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/sj.tpj.6500482PMID 17923851
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

  2006cited by this paper
• Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide

  2006cited by this paper
• Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

  2006cited by this paper
• Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

  2006cited by this paper
• Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

  2006cited by this paper
• Haploview: analysis and visualization of LD and haplotype maps

  2005cited by this paper
• Transcriptional Regulation of the Human CYP2A6 Gene

  2005cited by this paper
• Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.

  2005cited by this paper
• The International HapMap Project Web site.

  2005cited by this paper
• Identification and Phenotype Characterization of Two CYP3A Haplotypes Causing Different Enzymatic Capacity in Fetal Livers

  2005cited by this paper
• Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes.

  2005cited by this paper
• Cyclosporine markedly raises the plasma concentrations of repaglinide

  2005cited by this paper
• Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

  2005cited by this paper
• Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4

  2005cited by this paper
• Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation.

  2005cited by this paper
• Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance

  2005cited by this paper
• Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics

  2005cited by this paper
• SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST

  2005cited by this paper
• CYP2C8 polymorphism frequencies among malaria patients in Zanzibar

  2005cited by this paper
• Human CYP2C8 Is Transcriptionally Regulated by the Nuclear Receptors Constitutive Androstane Receptor, Pregnane X Receptor, Glucocorticoid Receptor, and Hepatic Nuclear Factor 4α

  2005cited by this paper
• Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes.

  2004cited by this paper
• Distribution of Soluble Epoxide Hydrolase and of Cytochrome P450 2C8, 2C9, and 2J2 in Human Tissues

  2004cited by this paper
• Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping.

  2004cited by this paper
• A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

  2004cited by this paper
• The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.

  2004cited by this paper
• Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

  2004cited by this paper
• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

  2003cited by this paper
• The International HapMap Project

  2003cited by this paper
• Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

  2003cited by this paper
• Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.

  2003cited by this paper
• Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.

  2003cited by this paper
• Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

  2003cited by this paper
• CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.

  2002cited by this paper
• Gemfibrozil greatly increases plasma concentrations of cerivastatin

  2002cited by this paper
• Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.

  2002cited by this paper
• Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift.

  2002cited by this paper
• Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.

  2001cited by this paper
• Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

  2001cited by this paper
• A new statistical method for haplotype reconstruction from population data.

  2001cited by this paper
• Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.

  1999cited by this paper
• Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.

  1994cited by this paper
• Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.

  1989cited by this paper
• Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-data Imputation

  year unknowncited by this paper

• Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism

  2024cites this paper
• Rottlerin renders a selective and highly potent CYP2C8 inhibition to impede EET formation for implication in cancer therapy.

  2023cites this paper
• Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics.

  2022cites this paper
• Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect

  2022cites this paper
• The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data

  2022cites this paper
• Pharmacogenomics of Insulin Secretagogues in Pharmacodynamics, Pharmacokinetics and Adverse Reactions

  2021cites this paper
• Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters

  2021cites this paper
• Drug‐Metabolizing Enzymes and Drug Toxicity

  2021cites this paper
• Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children

  2019cites this paper
• Development of NIPAAm-PEG acrylate polymeric nanoparticles for co-delivery of paclitaxel with ellagic acid for the treatment of breast cancer

  2019cites this paper
• DDDT_A_226913 4405..4411

  2019cites this paper
• Principles of Pharmacogenomics

  2019cites this paper
• Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children

  2019cites this paper
• Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic

  2018cites this paper
• Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver

  2018cites this paper
• ABCB1 Variation Affects Myelosuppression, Progression‐free Survival and Overall Survival in Paclitaxel/Carboplatin‐treated Ovarian Cancer Patients

  2018cites this paper
• Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review.

  2018cites this paper
• Genomics and Drug-Metabolizing Enzymes and Its Application in Drug Delivery: Evaluating the Influence of the Microbiome

  2018cites this paper
• ABCB 1 variation affects myelosuppression , progression-free 1 survival , and overall survival in paclitaxel / carboplatin-treated 2 ovarian cancer patients 3

  2018influential citation
• The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population

  2017cites this paper
• Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.

  2017cites this paper
• Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS.

  2017cites this paper
• Prevalence of the genetic mutation Cyp2c8*5 in selected ethnic groups in Southern Ghana

  2016cites this paper
• Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes

  2016cites this paper
• Peroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8

  2015cites this paper
• Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation

  2015cites this paper
• Genetic Markers in the EET Metabolic Pathway Are Associated with Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage

  2015cites this paper
• Genetic factors affecting drug disposition in Asian cancer patients

  2015cites this paper
• Pharmacogenomics of glinides.

  2015cites this paper
• CYP450 and Ethnicity

  2014cites this paper
• We are all individuals… bioinformatics in the personalized medicine era

  2014cites this paper
• Role of CYP2C8 in the metabolism of montelukast and imatinib : Studies in vitro, in silico and in humans

  2014cites this paper
• ROLE OF CYTOCHROME P450 FATTY ACID METABOLISM IN THE PATHOPHYSIOLOGY OF SUBARACHNOID HEMORRHAGE

  2014cites this paper
• Principles of pharmacogenomics: Pharmacokinetic, pharmacodynamic, and clinical implications

  2013cites this paper
• Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

  2013cites this paper
• Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro

  2013cites this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cites this paper
• Germline pharmacogenetics of paclitaxel for cancer treatment.

  2013cites this paper
• Pharmacogenetic predictors of taxane-induced peripheral neuropathy

  2013cites this paper
• International Evaluation of Research and Doctoral Training at the University of Helsinki 2005-2010: RC-Specific Evaluation of IndiViDrug - Individual variability in drug response

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cites this paper
• Pharmacokinetics of montelukast and zafirlukast as affected by CYP inhibitors

  2012cites this paper
• Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues.

  2012cites this paper
• Using genome-wide association studies to identify genes important in serious adverse drug reactions.

  2012cites this paper
• Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo

  2011cites this paper
• Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2.

  2011cites this paper
• Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

  2011cites this paper
• CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

  2011cites this paper
• Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.

  2011cites this paper
• Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.

  2011cites this paper
• Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review

  2011cites this paper
• Microtubule-targeting drugs and personalization of cancer treatment.

  2011cites this paper
• Relevance of Nonsynonymous CYP2C8 Polymorphisms to 13-cis Retinoic Acid and Paclitaxel Hydroxylation

  2010cites this paper
• Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma.

  2010cites this paper
• Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects

  2010influential citation
• Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis

  2010influential citation
• Pharmacogenomics of paclitaxel.

  2010cites this paper
• Acute Taxol Toxicity: the Effects on Bone Marrow Mitotic Index and the Histology of Mice Hepatocytes

  2010cites this paper
• CYP2C9*3 Loss‐of‐Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin

  2010cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Global variation in CYP2C8–CYP2C9 functional haplotypes

  2009cites this paper
• Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.

  2009cites this paper
• Cytochrome P450-mediated drug interactions affecting lidocaine

  2009cites this paper
• Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

  2009cites this paper
• Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

  2008cites this paper
• STUDIES ON CYP2C8-MEDIATED DRUG INTERACTIONS

  2008cites this paper
• STUDIES ON CYP 2 C 8-MEDIATED DRUG INTERACTIONS

  2008influential citation
• Inhibition and induction of human cytochrome P450 enzymes: current status

  2008cites this paper
• Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

  2008cites this paper
• Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism

  2008cites this paper
• Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in Vitro

  2008cites this paper
• Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease

  2008cites this paper
• Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

  2008cites this paper
• Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

  2007cites this paper